The central principle of precision medicine is that genetic, environmental and lifestyle characteristics can be used to identify the optimal treatment strategy for patients based on specific sets of characteristics of patients with a disorder.
PharmetRx® A.I.
Afecta was founded on our proprietary computational engine for new drug discovery and clinical validation of precision therapeutics. Applying this technology has enabled us to efficiently discover new uses for existing drug compounds as well as design new derivative compounds with improved drug properties, reduced adverse effects, and greater potential efficacy. Since our inception we have continued to expand and advance the platform to include clinical prediction models that can reduce failures in late stage development.
Multi-Target Drugs
Chronic diseases and cancers are driven by dysregulation of multiple complex processes and pathways. Traditional drugs that act on a single target protein to treat these disorders are usually only moderately effective. Multi-Target compounds are more effective than traditional drugs because they interact synergistically with multiple targets and treat complex disease processes on many fronts. Afecta has been pioneering the discovery and development of Multi-Target drug compounds using computational analysis of multi-omics-based disease pathways and drug signature identification. Our lead drugs are designed to inhibit complex disease processes and pathways.
NanoRx®
Precision therapeutics means directly targeting the disease with minimal systemic exposure. The goal is to increase the concentration of the drug at the target site while minimizing interactions with other tissues and cells. NanoRx® is our drug delivery technology that utilizes engineered nanomaterials to create novel drug carriers enabling precise drug delivery, specific to the target disease. This technology enables us to improve drug efficacy and reduce adverse effects for a wide range of diseases in various therapeutic areas.